BTIG reiterates Buy on Spyre Therapeutics, holds $121 target

0 min read | Published on 01 Oct 2026, 07:59 PM |Updated on 01 Oct 2026, 07:59 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

BTIG reiterated a Buy rating on Spyre Therapeutics
Price target maintained at $121 per share
Analyst Julian Harrison issued the rating update

*this image is generated using AI for illustrative purposes only.

BTIG analyst Julian Harrison reiterated a Buy rating on Spyre Therapeutics (NASDAQ: SYRE) and maintained the $121 price target. This action signals continued confidence in the company's outlook without altering previous valuation assumptions.

The firm’s decision to hold both the rating and the target price indicates that recent developments or market conditions have not materially changed the investment thesis established in prior reports.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific clinical trial milestones for Spyre Therapeutics are expected to drive the stock toward the $121 price target?

How might upcoming FDA regulatory decisions on Spyre's lead candidates impact the current valuation assumptions?

In what ways could broader biotech sector volatility or interest rate changes challenge the maintenance of this price target?

Spyre Therapeutics grants equity inducement awards to employee

1 min read | Published on 05 Sept 2026, 02:47 AM |Updated on 05 Sept 2026, 02:47 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Spyre Therapeutics granted 2,106 stock options and 745 RSUs to a non-executive employee
Stock options carry an exercise price of $88.50, matching the Sept 1 closing price
Awards vest over time based on continuous service, with options having a 10-year term
Grants were approved under the 2018 Equity Inducement Plan to secure employment

*this image is generated using AI for illustrative purposes only.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) approved equity inducement awards for one non-executive employee to secure their employment with the clinical-stage biotechnology company.

The Compensation Committee of the Board of Directors authorized the grants on September 1, 2026, under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. The awards comply with Nasdaq Listing Rule 5635(c)(4).

Award Structure

The package includes stock options and restricted stock units (RSUs) with specific vesting schedules tied to continuous service.

Component	Quantity	Exercise Price	Term
Stock Options	2,106 shares	$88.50	10 years
RSUs	745 shares	N/A	N/A

The exercise price of $88.50 reflects the closing price per share of Spyre’s common stock on Nasdaq as reported on September 1, 2026.

Vesting Schedule

Stock options vest in two phases:

One-fourth (1/4th) of shares vest on the first anniversary of the employee’s start date.
One-forty-eighth (1/48th) of shares vest monthly thereafter.

RSUs vest in four equal installments of one-fourth (1/4th) each. These payments occur on February 15, May 15, August 15, or November 15, starting from the first applicable date after the employee’s start date.

Company Profile

Spyre Therapeutics develops next-generation therapies for immunology. Its pipeline features investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F, alongside rational combination programs.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the retention of this specific non-executive employee impact the timeline or success probability of Spyre's current immunology clinical trials?

Given the $88.50 exercise price, what does this valuation signal about Spyre's internal confidence in its near-term stock performance and pipeline milestones?

Will Spyre need to seek shareholder approval for additional equity inducement grants if it continues to hire key talent under Nasdaq Rule 5635(c)(4)?